PCSK9
Alirocumab and evolocumab are fully humanized monoclonal antibodies that bind free plasma PCSK9 Mechanism = Decrease level of PCSK9= less free PCSK9 is available in plasma to bind to LDL-R= Increased LDL-R allow the liver to remove more LDL-C Alirocumab Dose Hyperlipidemia, primary:Initial: 75 mg sq every 2 weeks...
Statin Therapy
For hyperlipidemia, statin decreases the risk of stroke Lipid lowering by other means (eg, fibrates, resins, diet) has no significant impact on stroke incidence May have anti-atherothrombotic properties May have a role in plaque stabilization, reduce inflammation, slow carotid arterial disease progression, improve endothelial function, and reduce embolic stroke...